Literature DB >> 17623832

The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation.

Jean-Emmanuel Filmont1, Christian Gisselbrecht, Xavier Cuenca, Laure Deville, Marjan Ertault, Pauline Brice, Eric De Kerviler, Josette Briere, Jérome Larghero, Jean-Luc Moretti, Nicolas Mounier.   

Abstract

BACKGROUND: In patients with lymphoma who had a poor prognosis, pretransplantation 18-fluorodeoxyglucose (FDG)-positron-emission tomography (PET) was important for the evaluation of response and outcome. However, little is known about the correlation of FDG-PET with post-transplantation PET. The current study was designed to ascertain whether positive pretransplantation PET images are modified by the conditioning regimen.
METHODS: Sixty consecutive patients who had achieved remission and underwent consolidation by autologous stem cell transplantation (ASCT) had PET images obtained before ASCT (after 3 or 4 chemotherapy cycles) and 100 days after ASCT. The correlation was explored between the presence of abnormal 18-FDG uptake (PET positive) or its absence (PET negative) and patient outcomes.
RESULTS: Before ASCT, 31 patients achieved complete remission (CR), and 23 patients achieved uncertain CR. Before ASCT, 44 patients (75%) were had negative PET images; and, after ASCT, 48 patients (80%) had negative PET images. One year after ASCT, the estimated event-free survival (EFS) rate was 80% in patients who had negative pre-ASCT PET images compared with 43% in patients who had positive pre-ASCT PET images (P = .0002). The EFS rate was 81% in patients who had negative post-ASCT PET images compared with 25% in patients who had negative post-ASCT PET images (P < .0001). In multivariate analysis, only the results for pre- and post-ASCT PET images retained prognostic value, with relative risks of failure estimated at 4.9 and 11.9, respectively.
CONCLUSIONS: A positive pre-ASCT PET image indicated a high risk of ASCT failure, which was increased by a positive post-ASCT PET image. For patients with lymphoma who have positive pre-ASCT PET images, more investigations using new treatment approaches will be required. For patients who have negative pre-ASCT PET images, obtaining post-ASCT PET images does not seem to be mandatory. (c) 2007 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623832     DOI: 10.1002/cncr.22911

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.

Authors:  Teruhiko Terasawa; Issa J Dahabreh; Takashi Nihashi
Journal:  Oncologist       Date:  2010-06-29

Review 2.  FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard L Wahl
Journal:  Curr Opin Oncol       Date:  2008-03       Impact factor: 3.645

Review 3.  Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials.

Authors:  Loukia S Poulou; Loukas Thanos; Panayiotis D Ziakas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 4.  FDG PET/CT in children and adolescents with lymphoma.

Authors:  Regine Kluge; Lars Kurch; Françoise Montravers; Christine Mauz-Körholz
Journal:  Pediatr Radiol       Date:  2013-03-24

5.  Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.

Authors:  Anna Colpo; Ephraim Hochberg; Yi-Bin Chen
Journal:  Oncologist       Date:  2011-12-30

6.  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

Authors:  Xiuli Wang; Leslie L Popplewell; Jamie R Wagner; Araceli Naranjo; M Suzette Blanchard; Michelle R Mott; Adam P Norris; ChingLam W Wong; Ryan Z Urak; Wen-Chung Chang; Samer K Khaled; Tanya Siddiqi; Lihua E Budde; Jingying Xu; Brenda Chang; Nikita Gidwaney; Sandra H Thomas; Laurence J N Cooper; Stanley R Riddell; Christine E Brown; Michael C Jensen; Stephen J Forman
Journal:  Blood       Date:  2016-04-26       Impact factor: 22.113

7.  High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.

Authors:  L Castagna; R Crocchiolo; L Giordano; S Bramanti; C Carlo-Stella; B Sarina; A Chiti; E Mauro; S Gandolfi; E Todisco; M Balzarotti; A Anastasia; M Magagnoli; E Brusamolino; A Santoro
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

Review 8.  Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant.

Authors:  Eric Van Den Neste; Olivier Casasnovas; Marc André; Mohamed Touati; Delphine Senecal; Véronique Edeline; Aspasia Stamatoullas; Luc Fornecker; Bénédicte Deau; Thomas Gastinne; Oumédaly Reman; Isabelle Gaillard; Cécile Borel; Pauline Brice; Christophe Fermé
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

9.  Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma.

Authors:  J Palmer; T Goggins; G Broadwater; N Chao; M Horwitz; A Beaven; K Sullivan; R E Coleman; D Rizzieri
Journal:  Bone Marrow Transplant       Date:  2010-09-20       Impact factor: 5.483

10.  Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.

Authors:  Olivier Fitoussi; Karim Belhadj; Nicolas Mounier; Marie Parrens; Hervé Tilly; Gilles Salles; Pierre Feugier; Christophe Ferme; Loic Ysebaert; Jean Gabarre; Raoul Herbrecht; Maud Janvier; Eric Van Den Neste; Franck Morschhauser; Olivier Casasnovas; Hervé Ghesquieres; Bruno Anglaret; Sabine Brechignac; Corinne Haioun; Christian Gisselbrecht
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.